JAGUAR HEALTH, INC. Deferred Income Tax Expense (Benefit)
JAGUAR HEALTH, INC. (JAGX) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-04-07
- JAGUAR HEALTH, INC. deferred income tax expense (benefit) for the quarter ending 2017-12-31 was -$990.55K.
- JAGUAR HEALTH, INC. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- JAGUAR HEALTH, INC. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- JAGUAR HEALTH, INC. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- JAGUAR HEALTH, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-04-07 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-04-07 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 | ||
| 2021-12-31 | $0.00 10-K · filed 2023-03-24 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 | ||
| 2019-12-31 | $0.00 10-K · filed 2021-03-31 | ||
| 2018-12-31 | $0.00 10-K · filed 2020-04-03 | ||
| 2017-12-31 | -$990.55K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | -$13.18M 10-K · filed 2019-04-10 | |
| 2017-09-30 | -$12.19M 10-Q · filed 2018-11-19 | ||
| 2016-12-31 | $5.64M 10-K · filed 2017-02-15 | ||
| 2015-12-31 | $4.78M 10-K · filed 2017-02-15 | ||
| 2014-12-31 | $3.36M 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |